SurgiSil: Lip implant case shows looks can be deceiving

In October 2021, the Federal Circuit issued a two-and-half page decision in In re: SurgiSil, 14 F.4th 1380 (2021). Despite clocking in at just over 600 words, this small decision could have wide-ranging repercussions in the design patent jurisprudence, in three potential ways.

Already registered?

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk

More on this story

Americas

J&J unit targets former employee over alleged mass data theft

17 March 2026 Janssen seeks injunctive relief after a forensic review uncovers mass downloads of trade secrets spanning oncology, neuroscience and immunology portfolios.

Americas

Six Summit takeaways: In-person IP, agentic AI and ‘infollution’ risks

12 March 2026 The event unpacked how technology, litigation trends, and global events are adding complexity while also offering benefits for legal teams under pressure to reduce costs.

Americas

Astellas blocks generic version of key urology drug until 2030

12 March 2026 The pharma company has successfully enforced its patents against Ascent’s proposed mirabegron copy, shortly after inking licensing deals elsewhere over the medication.

More features

Sandoz strikes fresh biosimilar deal with South Korean biotech

J&J unit targets former employee over alleged mass data theft

INTA: ‘New normal’ for in-house counsel as budgets fall

Mylan withdraws defence claims against Novo in Wegovy dispute

Six Summit takeaways: In-person IP, agentic AI and ‘infollution’ risks

Astellas blocks generic version of key urology drug until 2030

Orrick adds specialist licensing partner in Silicon Valley

GSK inks licensing deal for liver disease drug

SurgiSil: Lip implant case shows looks can be deceiving

More on this story

Editor's picks

Editor's picks

More features